ja ist es. Ich frage mich, ob der CRC Stuhl Filz da seine Hände de im Spiel hat.
Fakt ist, dass mit 150 Mio für die Marketing Massnahmen der Test ein erfolg wird. Nur - werden die nicht durch uns Aktionäre aufgebracht. Test mit Erstattung und weiterem Verbesserungspotential ist aber eine cash cow für jeden Übernehmer.
Unser AR Walt von Roche müsste das ja einschätzen können.
Franz Thomas Walt (*1959, Switzerland) holds an MBA of City University, Bellevue, Washington and completed executive programs at Columbia University, IMD, Switzerland, London Business School and INSEAD, France.
Following his studies, Mr. Walt spent over 30 years in leadership roles at two of the worlds largest healthcare companies, Siemens Healthineers and Roche. Between 1989 and 2011 he held various positions of increasing responsibility in pharma and diagnostics, which includes CEO, Managing Director and President roles, in various geographic regions for Roche Diagnostics. Most recently he served eight years as a member of the Roche Diagnostics Executive Committee (DiaEC). After Roche, he worked for Siemens Healthineers AG between 2012 and 2017, most recently as President of Laboratory Diagnostics. Since 2018, he has been Chief Executive Officer of NASDAQ-listed Quotient Ltd. Eysins, Switzerland. |